Clinical Utilization of Newly Approved Oncology Medications
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of different medications vary from one individual to another and from
one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic and
pharmacoepidemiology has evolved recently.
There are multiple examples of oncology drugs being more effective in certain ethnic
population compared to other. For example, irinotecan combined with cisplatin was very
effective drug in the management of small cell lung cancer in the Japanese patients while an
identical study done in the US revealed no major benefit to this combination in American
population